Program
tislelizumab
Also written as “Tislelizumab”, “BGB-A317” and “Tislelizumab Injection plus Oxaliplatin for Injection plus Capecitabine Tablets (phase III)(phase III)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Esophageal Squamous Cell Carcinoma · Carcinoma, Hepatocellular · Stomach Neoplasms · Hodgkin Disease, led by 21 companies.
Drug pageTislelizumab: every studyMany companies study it; this page follows only the 74 they lead. All 434 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BeOne Medicines | 539 open or running | phase 3since Nov 27, 2017 | Mar 26, 2015 | Nov 2026phase 2 · NCT03736889 |
| RemeGenits history only | 22 open or running | phase 3since Apr 17, 2025 | Apr 17, 2025 | May 15, 2028phase 3 · NCT06944496 |
| Antengeneits history only | 10 open or running | phase 2since May 25, 2020 | May 25, 2020 | none ahead |
| Beijing Aosaikang Pharmaceuticalits history only | 11 open or running | phase 2since Nov 21, 2022 | Nov 21, 2022 | none ahead |
| Beijing Biostar Pharmaceuticalsits history only | 11 open or running | phase 2since Sep 18, 2026 | Sep 18, 2026 | Sep 20, 2028phase 2 · NCT07842276 |
| BriaCell Therapeuticsits history only | 11 open or running | phase 2since Jun 11, 2024 | Jun 11, 2024 | none ahead |
| Bristol-Myers Squibbits history only | 10 open or running | phase 3since Nov 9, 2018 | Nov 9, 2018 | none ahead |
| Changchun GeneScience Pharmaceuticalits history only | 10 open or running | phase 1since Jun 16, 2022 | Jun 16, 2022 | none ahead |
| HUTCHMEDits history only | 10 open or running | phase 2since Sep 23, 2020 | Sep 23, 2020 | none ahead |
| Immix Biopharmaits history only | 11 open or running | phase 2since Jan 4, 2023 | Jan 4, 2023 | none ahead |
| Immune-Onc Therapeuticsits history only | 10 open or running | phase 1since Aug 12, 2022 | Aug 12, 2022 | none ahead |
| Jazz Pharmaceuticalsits history only | 11 open or running | phase 3since Nov 5, 2021 | Nov 5, 2021 | none ahead |
| Jiangsu Healthy Life Innovation Medical Technologyits history only | 11 open or running | phase 2since Mar 19, 2024 | Mar 19, 2024 | none ahead |
| Jiangsu Yahong Meditech Co., Ltd aka Asierisits history only | 10 open or running | phase 2since Mar 21, 2021 | Mar 21, 2021 | none ahead |
| Leap Therapeuticsits history only | 10 open or running | phase 2since Apr 23, 2020 | Apr 23, 2020 | none ahead |
| Nanjing Leads Biolabsits history only | 10 open or running | phase 2since Aug 22, 2022 | Aug 22, 2022 | none ahead |
| Novartisits history only | 10 open or running | phase 3since Mar 17, 2023 | Mar 17, 2023 | none ahead |
| Shanghai Gopherwood Biotechits history only | 10 open or running | phase 2since Aug 15, 2022 | Aug 15, 2022 | none ahead |
| Shanghai Kanda Biotechnologyits history only | 11 open or running | phase 2since May 24, 2023 | May 24, 2023 | none ahead |
| Sino Biopharmaceuticalits history only | 11 open or running | phase 2since Feb 9, 2025 | Feb 9, 2025 | none ahead |
| Suzhou Zelgen Biopharmaceuticalsits history only | 11 open or running | phase 2since Jul 25, 2025 | Jul 25, 2025 | Dec 2027phase 2 · NCT07099547 |
Also a collaborator on its studies: Myriad Genetic Laboratories.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of BeOne Medicines only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 38 earlier studies, Mar 26, 2015 to Jul 3, 2021.
- Jun 9, 2017Named tislelizumabINNProposed as its International Nonproprietary Name in WHO's List 117
- Oct 20, 2021Phase 2 study in Colorectal NeoplasmsNCT05116085 · 33 enrolled · China
- Feb 10, 2022Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT05267054 · 53 enrolled · China
- Jul 14, 2022Phase 2 study in Esophageal Squamous Cell CarcinomaNCT05461794 · 96 enrolled · China
- Aug 8, 2022Phase 1 study in Solid TumorNCT05494762 · 55 enrolled · United States, Australia
- Sep 29, 2022Phase 3 study in Carcinoma, HepatocellularNCT05564338
- Oct 10, 20222 phase 2 studiesNCT05577702, NCT05609370
- Nov 23, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05635708 · 418 enrolled · United States, Australia, Brazil and more
- Dec 1, 2022Phase 1 study in Solid TumorsNCT05644626
- Dec 15, 2022Phase 2 study in Carcinoma, Transitional CellNCT05661955 · 113 enrolled · China
- Jul 31, 2023Phase 1 study in Advanced Solid TumorNCT05981703 · 337 planned · United States, Australia, China and more
- Oct 16, 2023Phase 1 study in Carcinoma, Non-Small-Cell LungNCT06091943 · 62 enrolled · China, Georgia, Moldova
- Jun 20, 2025Phase 3 study in Metastatic Gastric AdenocarcinomaNCT07043400 · 351 planned · United States, Argentina, Austria and more
- Apr 21, 2026Phase 2 study in Esophageal Squamous Cell CarcinomaNCT07554521 · 30 planned · United States
- Jul 22, 2026Phase 2 study in Esophageal Squamous Cell CarcinomaNCT07733180 · 30 planned · Japan
Ahead
- Nov 2026Primary completion: phase 2 study in MSI-H/dMMR Solid TumorsNCT03736889
- Jun 30, 2027Primary completion: phase 3 study in Carcinoma, Transitional CellNCT03967977
- Oct 30, 2027Primary completion: phase 3 study in Metastatic Gastric AdenocarcinomaNCT07043400
- Feb 28, 2028Primary completion: phase 2 study in Esophageal Squamous Cell CarcinomaNCT07733180
TargetBeta
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 53 BeOne Medicines leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07733180Esophageal Squamous Cell Carcinoma · Japan | 2 | Recruiting | Feb 28, 2028 | 30 |
| NCT07554521Esophageal Squamous Cell Carcinoma · United States | 2 | Recruiting | Dec 31, 2031 | 30 |
| NCT07043400Metastatic Gastric Adenocarcinoma · United States, Argentina, Austria and more | 3 | Recruiting | Oct 30, 2027 | 351 |
| NCT06091943Carcinoma, Non-Small-Cell Lung · China, Georgia, Moldova | 1 | Completed | Jul 31, 2025 | 62 |
| NCT05981703Advanced Solid Tumor · United States, Australia, China and more | 1 | Recruiting | Feb 28, 2029 | 337 |
| NCT05661955Carcinoma, Transitional Cell · China | 2 | Active, not recruiting | May 27, 2025 | 113 |
| NCT05644626Solid Tumors | 1 | Withdrawn | Mar 2025 | 0 |
| NCT05635708Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more | 2 | Completed | Dec 19, 2025 | 418 |
| NCT05609370Colorectal Neoplasms · United States, Australia, China and more | 2 | Active, not recruiting | May 23, 2025 | 113 |
| NCT05577702Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Dec 13, 2024 | 121 |
| NCT05564338Carcinoma, Hepatocellular | 3 | Withdrawn | Apr 30, 2027 | 0 |
| NCT05494762Solid Tumor · United States, Australia | 1 | Terminated | Feb 24, 2025 | 55 |
| NCT05461794Esophageal Squamous Cell Carcinoma · China | 2 | Terminated | Feb 26, 2024 | 96 |
| NCT05267054Lymphoma, Large B-Cell, Diffuse · China | 2 | Completed | Aug 30, 2024 | 53 |
| NCT05116085Colorectal Neoplasms · China | 2 | Completed | Sep 26, 2023 | 33 |
| NCT05014828Advanced Solid Tumor · China | 2 | Completed | Oct 20, 2023 | 58 |
| NCT04974047Resectable Esophageal Squamous Cell Carcinoma · China | 2 | Completed | Apr 17, 2023 | 70 |
| NCT04948697Advanced Hepatocellular Carcinoma · China, Taiwan | 2 | Completed | Feb 1, 2024 | 94 |
| NCT04921358Carcinoma, Non-Small-Cell Lung · Australia, China | 3 | Terminated | Dec 20, 2023 | 377 |
| NCT04746924Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Terminated | May 30, 2025 | 669 |
| NCT04716634Advanced Solid Tumors · China, Korea, Republic of | 2 | Completed | Feb 22, 2024 | 84 |
| NCT04693234Uterine Cervical Neoplasms · Bulgaria, China, Korea, Republic of and more | 2 | Completed | Jun 16, 2022 | 178 |
| NCT04649385Advanced Solid Tumor · United States, Australia, China and more | 1 | Completed | Oct 17, 2025 | 157 |
| NCT04866017Carcinoma, Non-Small-Cell Lung · United States, Australia, China and more | 3 | Terminated | Oct 17, 2023 | 63 |
| NCT04486391Classical Hodgkin Lymphoma · China | 3 | Terminated | Oct 13, 2025 | 3 |
| NCT04401800Carcinoma, Hepatocellular · China | 2 | Completed | Dec 1, 2022 | 64 |
| NCT04379635Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Aug 21, 2023 | 453 |
| NCT04318080Classical Hodgkin Lymphoma · United States, Australia | 2 | Completed | Dec 12, 2022 | 46 |
| NCT04276493Breast Neoplasms · China, South Korea, Taiwan | 2 | Completed | Dec 7, 2023 | 71 |
| NCT04164199Advanced Malignancies · United States, Australia, China and more | 3 | Completed | May 23, 2026 | 404 |
| NCT04068519Advanced Solid Tumors · China | 2 | Completed | Dec 1, 2018 | 300 |
| NCT04005716Small Cell Lung Carcinoma · China | 3 | Completed | Apr 19, 2023 | 457 |
| NCT04004221Locally Advanced or Metastatic Urothelial Bladder Cancer · China, Korea, Republic of | 2 | Completed | Sep 16, 2019 | 113 |
| NCT03967977Carcinoma, Transitional Cell · China, Taiwan | 3 | Active, not recruiting | Jun 30, 2027 | 420 |
| NCT03957590Esophageal Squamous Cell Carcinoma · China | 3 | Completed | Jan 8, 2025 | 370 |
| NCT03924986Recurrence · China, Taiwan, Thailand | 3 | Completed | Mar 26, 2021 | 263 |
| NCT03783442Esophageal Squamous Cell Carcinoma · United States, Australia, Belgium and more | 3 | Completed | Feb 28, 2022 | 649 |
| NCT03777657Gastric, or Gastroesophageal Junction Adenocarcinoma · United States, China, France and more | 3 | Completed | Feb 28, 2023 | 997 |
| NCT03736889MSI-H/dMMR Solid Tumors · China | 2 | Recruiting | Nov 2026 | 200 |
| NCT03744468Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in · United States, Australia, France and more | 2 | Completed | Feb 6, 2025 | 147 |
| NCT03666143Advanced Solid Tumors · Australia, China | 1 | Completed | Jan 5, 2023 | 216 |
| NCT03663205Carcinoma, Non-Small-Cell Lung · China | 3 | Completed | Jan 23, 2020 | 334 |
| NCT03594747Carcinoma, Non-Small-Cell Lung · China | 3 | Completed | Sep 30, 2020 | 360 |
| NCT03493451Lymphoma, T-Cell, Peripheral · Canada, China, France and more | 2 | Completed | Apr 21, 2021 | 77 |
| NCT03432598Lung Neoplasms · China | 2 | Completed | Feb 25, 2019 | 54 |
| NCT03430843Esophageal Squamous Cell Carcinoma · United States, Belgium, China and more | 3 | Completed | Dec 1, 2020 | 512 |
| NCT03419897Carcinoma, Hepatocellular · China, France, Germany and more | 2 | Completed | Jun 30, 2021 | 249 |
| NCT03412773Carcinoma, Hepatocellular · United States, China, Czechia and more | 3 | Completed | Jul 11, 2022 | 684 |
| NCT03358875Carcinoma, Non-Small-Cell Lung · Brazil, Bulgaria, China and more | 3 | Completed | Jul 15, 2021 | 805 |
| NCT03209973Classical Hodgkin Lymphoma · China | 2 | Completed | Nov 2, 2020 | 70 |
| NCT02795182Lymphoma · Australia, China | 1 | Completed | Dec 18, 2020 | 75 |
| NCT02660034Solid Tumors · United States, Australia, France and more | 1 | Completed | Sep 9, 2020 | 229 |
| NCT02407990Advanced Cancer · United States, Australia, Korea, Republic of and more | 1 | Completed | Aug 12, 2020 | 451 |
How it is read
Names in the registry
- “Tislelizumab”, 57 entries
- “BGB-A317”, 2 entries
- “Tislelizumab Injection plus Oxaliplatin for Injection plus Capecitabine Tablets (phase III)(phase III)”, 1 entry
- “Tislelizumab (BGB-A317)”, 1 entry
- “Subcutaneous Tislelizumab”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 13 studies
- Esophageal Squamous Cell Carcinoma, 7 studies
- Carcinoma, Hepatocellular, 5 studies
- Stomach Neoplasms, 4 studies
- Hodgkin Disease, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.